3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
17
Terminated
6
Not yet recruiting
4
Unknown
3
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
CNS
1
Conditions
Breast Neoplasms
704
Carcinoma, Non-Small-Cell Lung
470
Prostatic Neoplasms
420
Neoplasms
380
Multiple Myeloma
264
Colorectal Neoplasms
261
Lung Neoplasms
247
Neoplasm Metastasis
229
Melanoma
215
Ovarian Neoplasms
191
Leukemia, Myeloid, Acute
189
Pancreatic Neoplasms
182
Squamous Cell Carcinoma of Head and Neck
163
Recurrence
147
Carcinoma, Renal Cell
145
Lymphoma
142
Glioblastoma
138
Lymphoma, Non-Hodgkin
135
Stomach Neoplasms
128
Triple Negative Breast Neoplasms
127
Brain Neoplasms
124
Carcinoma, Hepatocellular
123
Leukemia, Lymphocytic, Chronic, B-Cell
122
Uterine Cervical Neoplasms
117
Head and Neck Neoplasms
117
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Urinary Bladder Neoplasms
113
Lymphoma, Large B-Cell, Diffuse
105
Sarcoma
102
Lymphoma, Follicular
100
Interventions
ibrutinib
1
Standard of Care
1
Lenalidomide
1
Atorvastatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
Neurologic Manifestations
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled
NCT04904536
2025-04-10
STRONGER
The George Institute
Phase 3
Active not recruiting
190 enrolled